BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).

被引：6
|
作者：
El-Rayes, Bassel F.
Richards, Donald A.
Cohn, Allen Lee
Richey, Stephen Lane
Feinstein, Trevor
Kundranda, Madappa N.
El-Khoueiry, Anthony B.
Melear, Jason M.
Braiteh, Fadi S.
Hitron, Matthew
Ortuzar, Waldo Feliu
Khan, Waheed
Xu, Bo
Li, Wei
Li, Youzhi
Li, C. J.
机构：
[1] Winship Canc Inst, Atlanta, GA USA
[2] Texas Oncol, Tyler, TX USA
[3] Rocky Mt Canc Ctr, Denver, CO USA
[4] US Oncol Network, McKesson Specialty Hlth, Texas Oncol, Ft Worth, TX USA
[5] Piedmont Canc Inst, Fayetteville, GA USA
[6] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[7] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[8] Texas Oncol, Round Rock, TX USA
[9] US Oncol Network, McKesson Specialty Hlth, The Woodlands, TX USA
[10] Boston Biomed Inc, Cambridge, MA USA
[11] Eli Lilly & Co, Indianapolis, IN 46285 USA
[12] Boston Biomed Inc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4077
引用
收藏
页数：5
相关论文
共 44 条
  • [1] BBI608-201GBM: A phase Ib/II clinical study of napabucasin (BBI608) in combination with temozolomide (TMZ) for adult patients with recurrent glioblastoma (GBM).
    Mason, Warren P.
    de Robles, Paula
    Borodyansky, Laura
    Hitron, Matthew
    Ortuzar, Waldo Feliu
    Khan, Waheed
    Xu, Bo
    Li, Wei
    Li, Youzhi
    Li, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] A phase Ib study of BBI608 in combination with FOLFIRI with and without bevacizumab in patients (pts) with advanced colorectal cancer (CRC)
    Hubbard, Joleen Marie
    Jonker, Derek J.
    O'Neil, Bert H.
    Halfdanarson, Thorvardur Ragnar
    Grothey, Axel
    Li, Youzhi
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] BBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer
    Larson, Tim
    Ortuzar, Waldo Feliu
    Bekaii-Saab, Tanios S.
    Becerra, Carlos
    Ciombor, Kristen Keon
    Hubbard, Joleen Marie
    Edenfield, William Jeffery
    Shao, Spencer H.
    Grothey, Axel
    Borodyansky, Laura
    Xu, Bo
    Li, Wei
    Li, Youzhi
    Li, Chiang
    Khan, Waheed
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
    Shinozaki, Eiji
    Kawazoe, Akihito
    Kuboki, Yasutoshi
    Komatsu, Yoshito
    Nishina, Tomohiro
    Hara, Hiroki
    Yuki, Satoshi
    Shitara, Kohei
    Bando, Hideaki
    Kotani, Daisuke
    Takahashi, Koji
    Mikamoto, Yuichi
    Hasegawa, Hiromi
    Hirano, Nami
    Nomura, Shogo
    Togashi, Yosuke
    Nishikawa, Hiroyoshi
    Sato, Akihiro
    Ohtsu, Atsushi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
    Kawazoe, Akihito
    Kuboki, Yasutoshi
    Komatsu, Yoshito
    Nishina, Tomohiro
    Shinozaki, Eiji
    Hara, Hiroki
    Yuki, Satoshi
    Shitara, Kohei
    Bando, Hideaki
    Takahashi, Koji
    Mikamoto, Yuichi
    Hasegawa, Hiromi
    Hirano, Nami
    Nomura, Shogo
    Togashi, Yosuke
    Nishikawa, Hiroyoshi
    Sato, Akihiro
    Ohtsu, Atsushi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
    Kuboki, Yasutoshi
    Kawazoe, Akihito
    Komatsu, Yoshito
    Nishina, Tomohiro
    Shinozaki, Eiji
    Hara, Hiroki
    Yuki, Satoshi
    Fukutani, Miki
    Tsukahara, Natsuko
    Hasegawa, Hiromi
    Hirano, Nami
    Nomura, Shogo
    Togashi, Yosuke
    Nishikawa, Hiroyoshi
    Sato, Akihiro
    Ohtsu, Atsushi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Iyer, Renuka
    Sonti, Sahithi
    Mahalingam, Devalingam
    Mukherjee, Sarbajit
    Chakraborty, Sayan
    Attwood, Kristopher
    George, Anthony
    Maguire, Orla
    Minderman, Hans
    Fountzilas, Christos
    CANCER RESEARCH, 2024, 84 (07)
  • [8] A phase Ib/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).
    Bekaii-Saab, Tanios S.
    Starodub, Alexander
    El-Rayes, Bassel F.
    O'Neil, Bert H.
    Shanda, Safi
    Ciombor, Kristen Keon
    Noonan, Anne M.
    Hanna, Wahid Tewfik
    Sehdev, Amikar
    Shaib, Walid Labib
    Mikhail, Sameh
    Neki, Anterpreet S.
    Oh, Cindy
    Li, Youzhi
    Li, Wei
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
    Ghassan K. Abou-Alfa
    Chia-Jui Yen
    Chih-Hung Hsu
    Joseph O’Donoghue
    Volkan Beylergil
    Shutian Ruan
    Neeta Pandit-Taskar
    Bolorsukh Gansukh
    Serge K. Lyashchenko
    Jennifer Ma
    Peter Wan
    Yu-Yun Shao
    Zhong-Zhe Lin
    Catherine Frenette
    Bert O’Neil
    Lawrence Schwartz
    Peter M. Smith-Jones
    Toshihiko Ohtomo
    Takayoshi Tanaka
    Hideo Morikawa
    Yuko Maki
    Norihisa Ohishi
    Ya-Chi Chen
    Tamara Agajanov
    Frederic Boisserie
    Laura Di Laurenzio
    Ray Lee
    Steven M. Larson
    Ann-Lii Cheng
    Jorge A. Carrasquilo
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 421 - 429
  • [10] Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Yen, Chia-Jui
    Hsu, Chih-Hung
    O'Donoghue, Joseph
    Beylergil, Volkan
    Ruan, Shutian
    Pandit-Taskar, Neeta
    Gansukh, Bolorsukh
    Lyashchenko, Serge K.
    Ma, Jennifer
    Wan, Peter
    Shao, Yu-Yun
    Lin, Zhong-Zhe
    Frenette, Catherine
    O'Neil, Bert
    Schwartz, Lawrence
    Smith-Jones, Peter M.
    Ohtomo, Toshihiko
    Tanaka, Takayoshi
    Morikawa, Hideo
    Maki, Yuko
    Ohishi, Norihisa
    Chen, Ya-Chi
    Agajanov, Tamara
    Boisserie, Frederic
    Di Laurenzio, Laura
    Lee, Ray
    Larson, Steven M.
    Cheng, Ann-Lii
    Carrasquilo, Jorge A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (02) : 421 - 429
12345